Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that the FDA has granted Orphan Drug Designation to UX701 for treating Wilson disease, a rare metabolic disorder. This designation marks an important milestone in UX701's development, addressing a significant unmet need as current treatments often lead to severe side effects. UX701 is an investigational gene therapy aimed at normalizing copper metabolism in the liver. The company plans to file an IND application by the end of the year.
The press release discusses the presentation of data from a Phase 1/2 study of GTX-102, an experimental treatment for Angelman syndrome, at the FAST Global Summit. Key findings indicate initial clinical activity, as reflected in positive EEG results and improvements in communication scores among patients. Importantly, there were no new serious adverse events reported. The companies aim to resume the trial with a modified design to minimize risks observed at higher doses. GTX-102 has received multiple FDA designations, emphasizing its potential in treating this rare disease.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at two upcoming investor conferences. The Piper Sandler's 32nd Annual Healthcare Conference will be held on December 1, 2020, with a pre-recorded presentation available on the company's website. Additionally, Kakkis will present at the Evercore ISI HealthCONx Conference on December 2, 2020, at 1:00 PM ET. A live webcast will be accessible via the company's site, with replays available for 90 days.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced plans to construct a 100,000 square foot gene therapy manufacturing facility in Bedford, Massachusetts. This state-of-the-art facility will allow in-house production of their AAV-based gene therapies, including DTX301, DTX401, and UX701. The facility is projected to create 100 to 150 jobs over five years. Construction is underway, with completion expected in 2023. The facility will improve production processes and scalability to meet demand for Ultragenyx's clinical and approved products.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at two upcoming investor conferences: the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10, 2020, at 2:00 PM ET, and the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 3:00 PM ET. Live and archived webcasts of the presentations will be available on the company's website for 90 days. Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases, with an experienced management team committed to urgent and efficient drug development.
Ultragenyx Pharmaceutical (NASDAQ:RARE) has successfully completed an underwritten public offering of 5,111,110 shares of common stock at $90.00 per share, raising approximately $435.4 million in net proceeds after underwriting costs. The offering included the full exercise of an option for an additional 666,666 shares by underwriters. J.P. Morgan, Goldman Sachs, BofA Securities, and Cowen served as joint book-running managers for this offering. Ultragenyx focuses on developing novel therapies for rare genetic diseases, reinforcing its commitment to urgent drug development.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has announced the pricing of an underwritten public offering of 4,444,444 shares at $90.00 per share, aiming to raise approximately $400 million in gross proceeds. The offering's close is anticipated around November 2, 2020, subject to customary closing conditions. Underwriters include J.P. Morgan, Goldman Sachs, BofA Securities, and Cowen, with an option to purchase an additional 666,666 shares. This strategic capital raise aligns with the company's commitment to developing therapies for rare genetic diseases.
Ultragenyx Pharmaceutical (NASDAQ:RARE) announced a public offering of up to $400 million in common stock, with an option for underwriters to purchase an additional $60 million within 30 days. The offering is subject to market conditions and does not guarantee completion. Major banks involved include J.P. Morgan, Goldman Sachs, BofA Securities, and Cowen. The funds raised will be utilized for the development of therapies aimed at serious rare genetic diseases, reinforcing Ultragenyx's commitment to addressing high unmet medical needs.
Ultragenyx Pharmaceutical reported Q3 2020 revenues of $81.5 million, with Crysvita generating $37.3 million. The company raised the lower end of its Crysvita revenue guidance to $130 million from $125 million, with a total expected range of $130 million to $140 million. The launch of Dojolvi yielded $3.9 million in sales. However, operating expenses were $131.8 million, leading to a net loss of $68.8 million for the quarter. Notably, the interim data for GTX-102 shows promise for Angelman Syndrome, though serious adverse events were reported.
GeneTx Biotherapeutics and Ultragenyx Pharmaceutical (NASDAQ: RARE) announced positive interim data from the Phase 1/2 study of GTX-102, an investigational treatment for Angelman syndrome. All five patients treated showed significant improvements in communication, behavior, and motor functions by day 128. However, serious adverse events related to lower extremity weakness were noted at the highest doses, prompting a pause in dosing. The study protocol will be amended to lower dosages and minimize side effects. Further data will be presented at the FAST Global Summit in December 2020.